Endoplasmic reticulum stress and monogenic kidney diseases in precision nephrology

Sun-Ji Park 1 · Yeawon Kim 1 · Ying Maggie Chen 1

Received: 6 April 2018 / Revised: 22 June 2018 / Accepted: 20 July 2018
© IPNA 2018

Abstract
The advent of next-generation sequencing (NGS) in recent years has led to a rapid discovery of novel or rare genetic variants in human kidney cell genes, which is transforming the risk assessment, diagnosis, and treatment of kidney disease. Mutations may lead to protein misfolding, disruption of protein trafficking, and endoplasmic reticulum (ER) retention. An imbalance between the load of misfolded proteins and the folding capacity of the ER causes ER stress and unfolded protein response. Mutations in nephrin (NPHS1), podocin (NPHS2), laminin β2 (LAMB2), and α-actinin-4 (ACTN4) have been shown to induce ER stress in HEK293 cells and podocytes in hereditary nephrotic syndromes; various founder mutations in collagen IV α-chains (COL4A) have been demonstrated to activate podocyte ER stress in collagen IV nephropathies; and mutations in uromodulin (UMOD) have been reported to trigger tubular ER stress in autosomal dominant tubulointerstitial kidney disease. Meanwhile, ER resident protein SEC63 may modify disease severity in autosomal dominant polycystic kidney disease. These findings underscore the importance of ER stress in the pathogenesis of monogenic kidney disease. Recently, we have identified mesencephalic astrocyte-derived neurotrophic factor (MANF) and cysteine-rich with EGF-like domains 2 (CRELD2) as urinary ER stress biomarkers in ER stress-mediated kidney diseases.

Keywords ER stress · Nephrotic syndrome · Alport syndrome · ADTKD · Gene mutation · Biomarker

Introduction
The endoplasmic reticulum (ER) is an essential organelle for folding, post-translational modifications, and trafficking of secreted and membrane proteins, and thus it is responsible for maintaining protein homeostasis (proteostasis) in all eukaryotic cells [1]. Environmental and genetic factors can disrupt normal protein folding processes, and thus cause accumulation of unfolded and misfolded proteins in the ER lumen, resulting in ER stress and activation of the unfolded protein response (UPR) (Fig. 1) [3]. The UPR aims to restore ER homeostasis and prevent cell death through the induction of ER chaperones, reduction of protein synthesis, and degradation of misfolded proteins using three major ER-resident transducers: inositol-requiring enzyme 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6) (Fig. 1) [3, 4].

As illustrated in Fig. 1, under ER stress conditions, misfolded and unfolded proteins can dissociate the ER chaperone protein Bip (immunoglobulin heavy chain-binding protein) from these three ER transducers, resulting in their activation and initiation of the UPR [1, 5]. Bifunctional protein kinase/endoribonuclease IRE1 induces unconventional splicing of X-box binding protein (XBP1) mRNA into XBP1s mRNA, encoding a potent transcriptional activator XBP1s that upregulates the expression of ER chaperones and genes related to ER-associated protein degradation (ERAD). IRE1 also recruits tumor necrosis factor receptor-associated factor 2 (TRAF2) and activates pro-apoptotic Jun N-terminal kinase (JNK) or caspase 12 signaling, leading to apoptosis [4–6]. PERK phosphorylates the α-subunit of eukaryotic translation initiation factor 2 (eIF2α). Phosphorylation of eIF2α leads to general inhibition of protein translation and selective upregulation of ATF4, a transcription factor inducing the expression of ER chaperones and genes that are related to autophagy and

© Ying Maggie Chen
ychen32@wustl.edu

1 Division of Nephrology, Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8126, St. Louis, MO 63110, USA

Published online: 11 August 2018
oxidative response. ATF4 also activates the expression of pro-apoptotic CCAAT/enhancer-binding protein homologous protein (CHOP). ATF6 translocates to the Golgi, where it is cleaved by site-1 protease and site-2 protease. The active form of ATF6 (p50ATF6) then moves into the nucleus, where it acts as a transcription factor to induce synthesis of ER chaperones.

The UPR is fundamentally a cell-protective response, but cells rendered dysfunctional due to severe or chronic ER stress are eliminated from the organism by ER stress-specific apoptosis, mediated by ER-resident caspase 12, Jun N-terminal kinase (JNK) or CCAAT/enhancer-binding protein homologous protein (CHOP). Mesencephalic astrocyte-derived neurotrophic factor (MANF) binds to BiP inside the ER, and the interaction is calcium-dependent. The image is modified from Xu et al. [2] with permission.

**Podocyte ER stress and hereditary nephrotic syndromes**

Primary nephrotic syndrome (NS), characterized by heavy proteinuria and hypoalbuminemia, is accompanied by increased risk of infection, venous thromboembolism, and progression to end-stage renal disease (ESRD). NS is often a life-threatening condition when occurring in the first year of life. Almost 100% of patients with congenital onset and 44% with infantile onset of NS have gene mutations with the overall mutation detection rate being as high as 52% in steroid-resistant pediatric NS patients [9]. Focal segmental glomerulosclerosis (FSGS) is the most prevalent NS and glomerular disease leading to kidney failure.

Seeminal advances in human genetics in past decades have identified NS as a primary podocytopathy with more than 30 mutated podocyte genes discovered in human NS/FSGS patients [10]. These mutated genes can be divided into the following categories: (a) slit diaphragm-associated molecules, including nephrin (NPHS1) and podocin (NPHS2) [11]; (b) podocyte cytoskeleton related molecules
such as α-actinin-4 (ACTN4) [12]; (c) podocyte transcription factors; and (d) adhesion and extracellular matrix molecules such as laminin β2 (LAMB2).

Emerging evidence has shown that podocyte ER stress and dysfunction due to genetic factors plays an important role in the pathogenesis of NS/FSGS. In cell culture studies, Liu L. et al. show that a large number of nephrin missense mutants, which cause autosomal recessive congenital NS of the Finnish type, are trapped inside the ER, most likely due to misfolding [13]. In addition, treatment with a chemical chaperone sodium 4-phenylbutyrate restores impaired trafficking of some disease-causing missense mutants and rescues these mutants from ER to the plasma membrane [14]. Similarly, Ohashi T. et al. report that R138Q mutation of podocin, one of the most common missense mutations in NPHS2 that is causally linked to the autosomal recessive type of steroid-resistant NS, is retained in the ER. Moreover, chemical chaperones glycerol, trimethylamine-N-oxide, and dimethyl sulfoxide (DMSO) elicit a cellular redistribution of R138Q podocin to the plasma membrane [15].

In mouse models, we have developed a podocyte ER stress-induced NS mouse model, which recapitulates Pierson syndrome patients carrying C321R-LAMB2 mutation. Pierson syndrome (OMIM 609049), caused by LAMB2 mutations, is characterized by NS and extrarenal ocular and neurologic manifestations [16–18]. Laminin, type IV collagen, nidogen, and sulfated proteoglycans comprise the glomerular basement membrane (GBM) [19] that is assembled by podocytes and glomerular endothelial cells [20]. Laminins are heterotrimetric glycoproteins containing one α, one β, and one γ chain. The major laminin heterotrimer in the mature GBM is laminin α5β2γ1, or LM-521 [21]. Laminin trimerization occurs in the ER [22]. Once trimers are secreted into the extracellular space, they polymerize to form the supramolecular laminin network [23, 24]. By utilizing a knock-out/transgenic strategy, we have demonstrated that podocyte ER stress induced by the C321R misfolded protein activates the ER stress-specific apoptotic signal CHOP and causes mild podocyte injury before significant proteinuria in vivo [25]. Meanwhile, in a mouse model of FSGS, Cybulsky et al. show that podocyte-specific expression of K256E α-actinin-4 transgene induces podocyte ER stress, which is associated with ubiquitination of the mutant protein and impairment of the ubiquitin-proteasome system [26].

Podocyte ER stress and collagen IV nephropathies

Type IV collagen has six chains, α1 to α6, encoded by three pairs of genes on chromosomes 2, 13, and X. Each chain has three domains: a short 7S domain at the N-terminus; a long, interrupted collagenous domain in the middle; and a non-collagenous domain at the C-terminus. The six distinct α chains are arranged into three different triple helical heterotrimeric protomers: (α1)2α2, (α3α4α5), and (α5)2α6, which take place in the ER. Secreted protomers polymerize to create collagen networks [27]. At early stages of glomerulogenesis, the (α1)2α2 network is a component of GBM, Bowman’s capsule, and mesangial matrix. During normal glomerulogenesis, most of the (α1)2α2 network is replaced by α3α4α5 in the GBM and by (α5)2α6 in Bowman’s capsule, with (α5)2α6 remaining in the subendothelial region of the GBM and in the mesangial matrix [28, 29]. Experiments in mice showed that podocytes, but not endothelial cells, synthesize the α3α4α5 network [30].

Alport syndrome (AS) and thin basement membrane nephropathy (TBMN) are collagen IV nephropathies and characterized by structural abnormalities in the GBM. Although both conditions typically present with hematuria, AS is associated with proteinuria, progressive renal failure, and extrarenal syndromes. In contrast, TBMN is characterized by isolated persistent or recurrent hematuria and generally never progresses toward ESRD. The hallmark of TBMN is diffuse attenuation of the GBM, which also resembles the ultrastructural changes of early AS patients or Alport carriers. AS and TBMN are also genetically heterogeneous diseases. Eighty-five percent of AS patients have the X-linked form due to mutations in COL4A5, whereas both autosomal AS and TBMN occur due to mutations in COL4A3/4 genes.

G1334E-COL4A3 mutation is known to be pathogenic in AS and endemic in Cyprus. When WT and mutant Col4α3 chains are overexpressed in human undifferentiated podocytes, microarray analysis shows that the overexpression of WT or mutant COL4A3 chains differentially activates the UPR pathway [31]. Similarly, in a knock-in mouse model carrying the G1332E-COL4A3 that is the mouse equivalent of human G1334E-COL4A3 mutation, which resembles AS, the UPR pathway is activated in the mutant glomeruli [31]. Moreover, in kidney biopsies from patients with TBMN carrying a heterozygous G1334E-COL4A3 mutation, BiP expression is increased in the glomeruli of these patients compared with expression from controls [31]. These results suggest that podocyte ER stress arising from the mutant collagen IV chains contributes to the pathogenesis of AS and TBMN.

Even more interesting, collagen (COL4A) mutations have been found to be the most frequent mutations underlying adult FSGS patients [32]. Recent studies have suggested that AS, TBMN, and FSGS are a spectrum of renal pathologies. In a study of 57 Greek-Cypriot families presenting glomerular microscopic hematuria (classical AS is excluded), with or without proteinuria or chronic kidney function decline, 8 heterozygous causative mutations in COL4A3/A4 genes are identified in 87 patients of 16 families (28.1%). Among these 16 families, 8 non-related families feature the founder mutation G1334E-COL4A3. Kidney biopsies, which are available in seven families, show dual diagnosis of TBMN and FSGS in...
six families and FSGS in one family. Overexpression of some mutations, including G871C, another founder mutation in the Cypriot population that predisposes to severe chronic kidney disease/ESRD, and G484R, induces the UPR in human podocytes [33].

**Tubular ER stress and autosomal dominant tubulointerstitial kidney disease (ADTKD)**

ADTKD is a monogenic form of renal tubulointerstitial fibrosis leading to chronic kidney disease. It represents as many as 25% of patients with inherited kidney disease, after exclusion of polycystic kidney disease and AS [34]. ADTKD is caused by mutations in *UMOD, MUC1, REN,* and *HNF1B.* Multiple names have been used in the past, including uromodulin kidney disease, familial juvenile hyperuricemic nephropathy, and medullary cystic kidney disease type 1 and type 2. In 2015, KDIGO proposed a new terminology ADTKD for this group of diseases [35]. ADTKD-*UMOD* is characterized by hyperuricemia, gout, alterations in urinary concentration, and progressive loss of kidney function [35, 36]. Proteinuria is typically mild or absent. ADTKD-*UMOD* is a phenotypically heterogeneous disorder manifested by variable age of disease onset, disease severity, and rate of disease progression among affected individuals within and between families, with patients reaching ESRD between the ages of 25 and 70 years or older [35].

Uromodulin (Tamm-Horsfall protein) is exclusively expressed in the thick ascending limb (TAL) of Henle’s loop. Human mature uromodulin, mainly localized at the apical plasma membrane of TAL cells [37], contains a signal peptide, three EGF-like domains, a central domain of unknown function, a zona pellucida domain, and a glycosylphosphatidylinositol (GPI)-anchoring site [36]. It is co-translationally inserted in the ER where GPI anchoring, formation of intramolecular disulfide bonds, and N-glycosylation take place [36]. Uromodulin has extremely high cysteine content and extensive disulfide bond formation resulting in extremely slow transit through the ER. Once uromodulin reaches the plasma membrane, proteolytic cleavage by a protease hepsin generates polymerization-competent monomers that are assembled into polymeric filaments and released to the urine [38].

In vitro and in vivo studies have shown that *UMOD* mutations can cause protein misfolding, ER retention, and ER stress activation in TAL cells [39–43]. By utilizing CRISPR (clustered regularly interspaced short palindromic repeats)-generated *Umod* C147W knock-in mice, which resemble human patients carrying the *UMOD* C148W mutation, it has been shown that tubular ER stress induced by the C147W mutant uromodulin activates tubular apoptosis and inhibits autophagy. In addition, TRIB3 may act as an intrinsic ER stress-mediated cell death mediator to sensitize UMOD-producing tubular cells to TNF (tumor necrosis factor) and TRAIL (TNF-related apoptosis-inducing ligand)-induced apoptosis. Most importantly, when the mutant mice are treated with the soluble recombinant fusion protein TNF receptor:Fc, a TNFα signaling antagonist, ER stress-mediated inflammation, apoptosis, and fibrosis are attenuated with improvement in renal function [44].

**SEC63 and autosomal dominant polycystic kidney disease (ADPKD)**

ADPKD is caused by mutations in either *PKD1* or *PKD2,* which encodes the integral membrane proteins polycystin-1 (PC1) and PC2, respectively. It has been shown that ER-resident proteins SEC63 and XBP1 can modify polycystic disease severity [45]. Mutations in *SEC63* lead to isolated autosomal dominant polycystic liver disease, and organ-specific inactivation of *Sec63* in mice produces cysts in both the liver and kidneys as the result of reduced PC1.

ER protein folding, modifications, and quality control are governed by several chaperone systems, which include HSP70 (BiP)/HSP40 (DnaJ proteins), HSP90, calnexin/calreticulin, and protein disulfide isomerases. SEC63 is a member of the HSP40 protein family, and it is associated with the SEC61 translocon complex that serves as a channel through which nascent polypeptides are co-translationally imported into the ER lumen for folding, modification, and subsequent trafficking. SEC63 contains a DnaJ domain, which is conserved in HSP40 proteins that act as co-chaperones [46]. Using murine genetic models, it has been demonstrated that SEC63 deficiency selectively activates the IRE1α-XBP1 branch of UPR, which is a compensatory mechanism, and activation of XBP1 can enhance functional PC1 biogenesis and ameliorate cystic disease in a murine model with reduced PC1 function [45]. Furthermore, compound inactivation of both SEC63 and XBP1 exacerbates the polycystic kidney phenotype in mice by suppressing cleavage at the G protein-coupled receptor proteolysis site in PC1, which is critical in PC1 maturation. In summary, these findings show that SEC63 function regulates IRE1α/XBP1 activation, and activation of XBP1 can protect against polycystic disease in the setting of impaired biogenesis of PC1 [45].
Discovery of urinary ER stress biomarkers in ER stress-mediated kidney disease

As ER stress has emerged as a signaling platform underlying the pathogenesis of various kidney diseases, there is an urgent need to develop ER stress biomarkers in the incipient stages of ER stress-induced kidney disease, when a kidney biopsy is not yet clinically indicated, for early therapeutic intervention. Recently, we have identified mesencephalic astrocyte-derived neurotrophic factor (MANF) and cysteine-rich with EGF-like domains 2 (CRELD2) as urinary ER stress biomarkers [47, 48].

MANF as a urine ER stress biomarker in mouse models

MANF, also known as arginine-rich mutated in early tumors, or ARMET, was first discovered by Dr. Commissiong’s group in 2003 as a new dopaminergic neurotrophic factor in astrocyte-conditioned medium [49]. MANF cDNA is encoded by a 4.3-kb gene with 4 exons and located on human chromosome 3 [49]. MANF is localized to the ER lumen, and ER stress-induced transcriptional upregulation of MANF is driven by an ER stress response element (ERSE)-II in the MANF promoter [50, 51]. ERSE-II (ACGTGGNCCAAT) contains two transcriptional factor recognition sequences: ACGTGG is recognized by ATF6 or XBP1, whereas CCAAT is recognized by nuclear transcriptional factor Y. It has been shown that both binding sites are required for the MANF induction by ER stress [50]. Meanwhile, MANF secretion is partly regulated by BiP via calcium-dependent interaction of MANF and BiP in the ER (Fig. 1) and the BiP-MANF complex levels decrease in response to ER calcium depletion.

We have shown that in our podocyte ER stress-induced hereditary NS mouse model in which podocyte ER stress is activated by C321R-LAMB2, MANF is induced and secreted by ER-stressed podocytes at early stage of proteinuria [25, 47]. Most importantly, MANF is easily detected in urine specimens from Tg-C321R mutants at the incipient stage of NS, but not from the controls. In addition, urinary MANF excretion increases during disease progression in the mutants [47]. Similarly, in the acute kidney injury mouse model triggered by an ER stressor tunicamycin or ischemia/reperfusion, significant upregulation of MANF at both transcriptional and translational levels is observed in the ER-stressed renal tubules before obvious renal histopathologic changes or elevation of serum creatinine (Cr) occur. Moreover, urinary MANF excretion concurrent with tubular cell ER stress precedes histologic or clinical manifestations of acute tubular injury [47].

CRELD2 as a urine ER stress biomarker in both mouse models and human diseases

CRELD2 was first identified as a novel ER stress-inducible gene through RNA analysis of Neuro2a mouse neuroblastoma cells treated with thapsigargin, which depletes ER calcium through inhibition of ER calcium uptake by ER calcium ATPase [52]. It is a ~50-kDa secretory glycoprotein that predominantly localizes to the ER and Golgi apparatus [52, 53]. Its promoter region, which is well conserved among various species, contains a typical ERSE (CGTGG-N9-ATTGG) that is positively regulated by the ER stress master regulator ATF6 [52]. It has also been reported that four C-terminal amino acids (REDL) play a crucial role in CRELD2 secretion and that BiP and MANF significantly enhance its secretion [53, 54]. However, very few studies have been carried out to characterize the intrinsic induction and secretion of CRELD2 in vitro and in vivo.

When mouse primary podocytes are treated for 24 h with tunicamycin, which activates ER stress by blocking N-linked glycosylation in the ER [55], or thapsigargin, both ER stressors induce expression of CRELD2, which is barely detectable in vehicle-treated cells. In addition, both ER stressors increase CRELD2 secretion into the culture medium by mouse podocytes, whereas in the absence of ER stress, there is little CRELD2 secretion [48]. These data suggest that upregulation and secretion of CRELD2 induced by ER stress is not a cell-type-specific response. Furthermore, in our podocyte ER stress-induced NS mouse model carrying the C321R-LAMB2 mutation in podocytes, CRELD2 are upregulated at both transcriptional and translational levels in the mutant podocytes compared with control podocytes. Most importantly, CRELD2 is easily detected in unprocessed urine specimens from C321R mutants, but not from control littermates, at the early stage of NS [48].

We also investigated CRELD2 as a urinary biomarker for detecting tubular ER stress in ADTKD-UMOD, a prototypical tubular ER stress disease [48]. Co-immunofluorescence (IF) staining of CRELD2 and uromodulin in human kidney biopsies showed that native uromodulin is enriched at the apical membrane of TAL cells (arrows, Fig. 2a). In sharp contrast, mutant H177-R185del uromodulin exhibits diffuse expression in the cytoplasm of TAL tubules and mutant W202S uromodulin displays a punctate perinuclear distribution within TAL cells (Fig. 2a). Intracellular and intraluminal protein aggregates are also noted in kidney biopsies harboring both mutations, reminiscent of defective intracellular trafficking and ER retention of uromodulin mutants (Fig. 2a). Moreover, CRELD2 is markedly enhanced and completely co-localized with mutant uromodulin in TAL cells (Fig. 2a). Finally, CRELD2 is easily detected in unconcentrated
urine from human ADTKD-UMOD patients, whereas urinary CRELD2 excretion is absent from all tested genetically unaffected controls by ELISA assay (Fig. 2b). These results demonstrate the superb ability of CRELD2 to discriminate between controls and ADTKD patients with tubular ER stress [48].

Our identification of CRELD2 as a sensitive, mechanistic ER stress biomarker for ADTKD-UMOD is important to research in this area, as it will provide a useful tool for clinical trials, overcoming the challenge posed by the slow rates of rise in serum Cr in these patients, which is the major reason why current clinical trials in ADTKD-UMOD cannot be performed.

Future directions

Accumulating evidence has highlighted the important role of ER stress and disrupted proteostasis in the pathogenesis of various monogenic glomerular and tubular diseases. However, mechanism-based therapies targeting at specific ER stress response elicited by individual mutations are still lacking. Thus, there is emergent need to conduct large-scale drug screening of chemical compound libraries, which is based on high-throughput functional assays, to identify lead compounds. By utilizing the newly developed CRISPR/Cas9 genome-editing system which enables targeted modification of endogenous genomic sequences with high efficiency, more knock-in mouse models carrying different ER stress-inducing mutations will be generated as pre-clinical models for drug testing. In addition, human-induced pluripotent stem cells (hiPSCs) directly derived from patients will be established for disease modeling, mechanistic investigation, and future drug discovery. These novel technologies will greatly facilitate the implementation of precision medicine in the translational studies of ER stress-mediated monogenic kidney diseases and may lead to development of highly targeted ER stress modulators for individual mutations.

Funding information Y.M.C. is supported by NIH grants R01 DK105056, R03DK106451, and K08DK089015, Halpin Foundation-American Society of Nephrology Research Grant, Faculty Scholar Award (MD-FR-2013-336) from the Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital, Clinical Scientist Development Award (2015100) from the Doris Duke Charitable Foundation, Career Development Award from the Nephrotic Syndrome Study Network (NEPTUNE), and Renal Translational Innovation Grant from Washington University Division of Nephrology. Y.M.C. is a member of Washington University Diabetes Research Center (supported by NIH P30 DK020579), Washington University Musculoskeletal Research Center (supported by NIH P30AR057235), and Washington University Institute of Clinical and Translational Sciences (UL1 TR000448).
Compliance with ethical standards

Conflict of interest A patent application entitled “Mesencephalic astrocyte-derived neurotrophic factor (MANF) as a urine biomarker for endoplasmic reticulum (ER) stress-related kidney disease” has been filed by Y.M. Chen and Washington University Office of Technology Management (serial no. 14730465, filed on June 4, 2015). Another patent application entitled “Methods of detecting biomarkers of endoplasmic reticulum (ER) stress-associated kidney diseases” has been filed by Y.M. Chen and Y. Kim and Washington University Office of Technology Management (serial no. 15664476, filed on July 31, 2017).

References


